Successful treatment with apremilast of severe psoriasis exacerbation during nivolumab therapy for metastatic melanoma

Dermatol Ther. 2021 Jan;34(1):e14653. doi: 10.1111/dth.14653. Epub 2020 Dec 21.

Authors

Caterina Foti¹, Marco Tucci², Luca Stingeni³, Katharina Hansel³, Lucia Lospalluti¹, Rosa Frisario¹, Roberta Giuffrida⁴, Paolo Romita¹

Affiliations

¹ Department of Biomedical Science and Human Oncology. Dermatological Clinic, University of Bari, Bari, Italy.
² Section of Medical Oncology, Department of Biomedical Sciences and Clinical Oncology (DIMO), University of Bari 'Aldo Moro', Bari, Italy.
³ Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy.
⁴ Dermatology Section, Department of Clinical & Experimental Medicine, University of Messina, Messina, Italy.

PMID: 33301205
DOI: 10.1111/dth.14653

No abstract available

Publication types

Letter

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Humans
Melanoma* / drug therapy
Nivolumab / adverse effects
Psoriasis* / diagnosis
Psoriasis* / drug therapy
Severity of Illness Index
Thalidomide / adverse effects
Thalidomide / analogs & derivatives

Substances

Anti-Inflammatory Agents, Non-Steroidal
Nivolumab
Thalidomide
apremilast